DCGI gives nod to Mylan labs to manufacture remdesivir1 min read . Updated: 03 Jul 2020, 08:19 AM IST
Gilead had signed non-exclusive voluntary licensing agreements with five generic pharma firms
The Drug Controller General of India (DCGI) has granted permission to Mylan laboratories to manufacture and market the anti-viral drug remdesivir for 'restricted emergency use' on hospitalised COVID-19 patients, a senior government official said on Thursday.
Login to enjoy exclusive benefits!
- Unlocked premium articles
- Personalized news
- Market Watchlist
- Insightful Newsletters & more